ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 121

In Vitro Human Enthesitis Model with Induced IL-17A and TNFα from CD4+ and CD8+ T Cells and Effect of Pharmacological Antagonism with Janus Kinase and Retinoic Acid Receptor-related Orphan Receptor γ Inhibition

Hannah Rowe1, Abdulla Watad 2, Charles Bridgewood 1, Tobias Russell 3, Darren Newton 4, Miriam Wittmann 5, Qiao Zhou 6, Almas Khan 7, Robert Dunsmuir 7, Peter Loughenbury 7, Richard Cuthbert 3 and Dennis McGonagle 6, 1Leeds Institute of Rheumatic and Muscoskeletal Medicine(LIRMM), University of Leeds, Leeds, United Kingdom, 2Department of Medicine “B”, Zabludowicz Center for Autoimmune Diseases Sheba Medical Center, Ramat-Gan, Israel, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM)University of Leeds, Leeds, England, United Kingdom, 4Leeds Institute of Rheumatic and Muscoskeletal Medicine, Leeds, United Kingdom, 5Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM)University of Leeds, Leeds, United Kingdom, 6University of Leeds, Leeds, United Kingdom, 7Leeds Teaching Hospitals NHS Trust, Leeds

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Th17, Treg and Enthesitis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Animal models of experimental spondyloarthritis (SpA), human genetics and therapies support a central role for adaptive immunity in disease pathogenesis.  However, there is very limited data on whether the human enthesis harbours conventional CD4+ and CD8+ T-cells

To investigate whether spinal enthesis including peri-entheseal bone and peripheral blood harboured resident CD4+ and CD8+ conventional T-cells and to evaluate the effects of therapy in blocking the production of pivotal SpA-related cytokines TNF and IL-17A. Additionally, to investigate T cell plasticity via gene expression of Th17 and Treg markers following in vitro induction of entheseal inflammation.

.

Methods: : Healthy interspinous ligament and spinous process with matched blood were harvested from patients undergoing elective surgery for the correction of mechanical spinal defects (n=13). Entheseal soft tissue (EST) and peri-entheseal bone (PEB) were separated and digested. . Following the isolation of CD4+ and CD8+ T-cells  lymphocytes from PEB and peripheral blood, the conventional T lymphocytes were investigated using ELISA’s and RNA extraction for qRT-PCR to assess T effector cell markers.  Cells were stimulated using an anti-CD3/CD2/CD28 beads with and without the presence experimental RORγt inhibitor (RORγti), Tofacitinib, methotrexate (MTX), and phosphodiesterase type 4 inhibitor (PDE4i).

Results: Following stimulation, CD4+ T-cells produced more TNF and IL-17A than CD8+ T-cells (p< 0.05), IL-17A was robustly detected in CD4+ but not CD8+ T-cells. TNF and IL-17A production from CD4+ T-cells was effectively inhibited by Tofacitinib (p< 0.05), while RORγti only reduced IL-17 secretion highlighting it’s specificity in the IL-17A signalling pathway. MTX and PDE4i treated cells had no significant impact on reducing IL-17A production in either cell population. MTX also had no impact on reducing TNF production in either cell population, however PDE4i treated cells did reduce TNF production in both cell populations in blood. CD4+ and CD8+ T-cells showed increased expression of the Treg lineage specific gene FOXP3 compared to DMSO control (p=0.002) where PDE4i and methotrexate treatment caused the highest relative expression fold change in CD4+ PEB and CD8+ blood respectively (4.33±0.97, 347.89±347.35). The pleiotropic cytokine TGFβ showed varying results in PEB and blood, with a complete downregulation in CD4+ PEB and an upregulation in CD8+ Blood, methotrexate treatment caused the highest relative expression fold change (19.66±17.78), which may suggest a Th17 phenotypic shift in PEB and a iTreg shift in CD8 Blood, this is also supported by RORC and IL-6 upregulation in CD4 PEB in PDE4i treated cells (p=0.045 and 0.001 respectively).

Conclusion: This is a novel finding of conventional CD4+ and CD8+ enthesis resident T-cells that exhibit regulatory transcript expression in health. Where TGFβ expression may highlight T cell plasticity, promoting a Th17 phenotype in PEB and iTreg phenotype in blood. Induced IL-17A was robustly inhibited by RORgt inhibition.  


Disclosure: H. Rowe, None; A. Watad, None; C. Bridgewood, None; T. Russell, None; D. Newton, None; M. Wittmann, None; Q. Zhou, None; A. Khan, None; R. Dunsmuir, None; P. Loughenbury, None; R. Cuthbert, None; D. McGonagle, AbbVie, 9, Abbvie, 2, 8, BMS, 9, Celgene, 2, 8, 9, Janssen, 2, 8, Johnson & Johnson, 9, Lilly, 2, 8, MSD, 9, Novartis, 2, 8, 9, Pfizer, 2, 8, 9, UCB, 8, 9.

To cite this abstract in AMA style:

Rowe H, Watad A, Bridgewood C, Russell T, Newton D, Wittmann M, Zhou Q, Khan A, Dunsmuir R, Loughenbury P, Cuthbert R, McGonagle D. In Vitro Human Enthesitis Model with Induced IL-17A and TNFα from CD4+ and CD8+ T Cells and Effect of Pharmacological Antagonism with Janus Kinase and Retinoic Acid Receptor-related Orphan Receptor γ Inhibition [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/in-vitro-human-enthesitis-model-with-induced-il-17a-and-tnf%ce%b1-from-cd4-and-cd8-t-cells-and-effect-of-pharmacological-antagonism-with-janus-kinase-and-retinoic-acid-receptor-related-orphan-recept/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-vitro-human-enthesitis-model-with-induced-il-17a-and-tnf%ce%b1-from-cd4-and-cd8-t-cells-and-effect-of-pharmacological-antagonism-with-janus-kinase-and-retinoic-acid-receptor-related-orphan-recept/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology